AZD8701, an Antisense Oligonucleotide Targeting FOXP3 Mrna, As Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.
Clinical cancer research an official journal of the American Association for Cancer Research(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined